Joint UNICEF–UNFPA–WHO Meeting for Manufacturers and Suppliers
Session 5.3: WHO Vaccines & Immunization Prequalification Track – 03 December 2024

WHO PQ: Clinical requirements

Olivier Lapujade
Vaccines & Immunization Devices Assessment Team (VAX)
Prequalification Team Unit (PQT)
Regulation and Prequalification Department (RPQ)
Access to Medicines and Health Products Division (MHP)
World Health Organization
Geneva, Switzerland

E-mail: vaccprequalification@who.int

Outline

- Important Notes
- Key Clinical Data – Questions
- Module 1
- Module 2
- Module 5

Important Notes

Note 1

- PQ procedure: WHO Technical Report Series 978, Annex 6, 2013
- https://www.who.int/publications/m/item/TRS-978-61st-report-annex-6

- Guidelines for good clinical practice TRS 850, Annex 3,1995
  https://iris.who.int/bitstream/handle/10665/37340/WHO_TRS_850.pdf?isAllowed=y&sequence=1#page=103&zoom=auto,-359,654

- Guideline on clinical evaluation of vaccine-TRS 1004
  https://www.who.int/publications/m/item/WHO-TRS-1004-web-annex-9

- TRS 927 (2005; non-clinical evaluation of vaccines)
  https://www.who.int/publications/m/item/annex1-nonclinical.p31-63

- Points to consider for manufacturers of human vaccines: clinical considerations for evaluation of vaccines for prequalification
  http://www.who.int/immunization_standards/vaccine_quality/pq_vaccine_evaluation/en/

- Any specific TRS and related WHO position paper

Important Notes

- Note 2
  - For vaccines originally licensed many years before application for prequalification, emphasis should be given to document history of safe and effective use.
- Note 3
  - Provision on request of raw data

Module 1 (WHO specific) – clinical related

Section 1.6 – Pre-Clinical and Clinical Information

1.6.1 - List of **pre-clinical studies sponsored by applicant** – not included in Module 2.6 and Module 4 of the application- including any conclusion(s) including preclinical studies performed after initial licensure of product (and the reasons for these studies) If none, indicate

1.6.2 - List of all **clinical trials sponsored by the applicant** relevant for the application – not included in Module 5.2 of the application – site, age, date, objectives, registration, GCP compliance, statement on conclusion

Section 1.6 – Pre-Clinical and Clinical Information

1.6.3 Cross reference to the final approved protocol by ERC and NRA

1.6.4 List of **any clinical trials** that are known to be **currently ongoing with the vaccine candidate**, not relevant to the current PQ application including the summary of details of the study plan and expected date of result (for example, clinical trials being conducted for a different use indication and/or with a different age group, etc.).

Section 1.6 – Pre-Clinical and Clinical Information

1.6.5 List of other studies with applicant product – not included in Module 5 - for which the applicant is not the sponsor.

–This list should be compiled from publications

1.6.6 Complementary clinical summary supporting the use of the product worldwide by UN agencies

–This applies to those cases where the vaccine will be used in a different way from the conditions in the marketing authorization.

Section 1.6 – Pre-Clinical and Clinical Information

1.6.7 Assessment Report from the NRA(s)

- The applicant should provide the reference NRA assessment reports or rationale why it cannot be provided.

1.6.8. Clinical Independent expert report

- This is important especially if the application for prequalification is based on the extrapolation of the existing clinical data to the likely circumstances of use after prequalification, and if the data are old or there is a doubt regarding the ethical or regulatory oversight of the trial, the report should discuss the degree of compliance with WHO GCP recommendations and current guidance regarding preclinical and clinical trials with vaccines". Discuss epidemiology and how the vaccine fits in the global context.

  – Provide the CV of the Expert.

1.6.9 Post marketing Safety documentation

1.6.9.1 Outline of the **post-marketing pharmacovigilance plan for the product or Risk Management Plan – must be relevant to UN supply**

1.6.9.2 Initial evaluation of vaccines that have been in the market for more than five years or reassessment of already prequalified vaccines (The latest PSUR may be provided)

- Outline of the applicant's procedures for the collection, onward notification and assessment of adverse events.
- **Listing of all reported serious AEFIs** for the vaccine in question in the **last five years or since the last WHO reassessment- type,** lot #, date and place of vaccination, patient age and initial, seriousness criteria, causality and outcome

1.6.9.3 List of **ongoing clinical studies for vaccines licensed within the last five years.** Add a **cross reference to Module 5** and any studies that may not be part of the CTD

Module 2

Module 2: Non-clinical and clinical Summaries

2.1 Common Technical Document Table of Contents (Modules 2-5)

2.4 Nonclinical Overview

2.5 Clinical Overview

2.6 Nonclinical written and tabulated summaries

2.7 Clinical Summary

Module 5

Module 5: Clinical information

5.1 Table of Contents of Module 5

5.2 Tabular Listing of All Clinical Studies according to development plan [site, age, date, CT registry, objectives, GCP compliance, statement on conclusion]. This table should include any changes that has occurred over time in formulations, manufacturing scales etc.

5.3 Clinical Study reports

5.4 Literature References

Key Clinical Data – Questions

- Is there data on consistency of 3 commercial lots? If not, why?
- Can the vaccine be co-administered with other vaccines?
- How extrapolable are this data – other population or WHO regions?
- What is the pharmacovigilance plan – considering UN market?
- What is the post marketing experience?

- Follow the recent guidelines rigorously
- Ask questions if anything is not clear to you
- Note that collaboration is key

Thank you